Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Herrera AF, Lin J, Kim E, Chakraborty S, Marinello P, Moskowitz CH. Armand P, et al. Among authors: vassilakopoulos tp. Blood. 2023 Sep 7;142(10):878-886. doi: 10.1182/blood.2022019386. Blood. 2023. PMID: 37319435 Free PMC article.
Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma.
Vassilakopoulos TP, Angelopoulou MK, Constantinou N, Karmiris T, Repoussis P, Roussou P, Siakantaris MP, Korkolopoulou P, Kyrtsonis MC, Kokoris SI, Dimopoulou MN, Variamis E, Viniou NA, Konstantopoulos K, Dimitriadou EM, Androulaki A, Patsouris E, Doussis-Anagnostopoulou IA, Panayiotidis P, Boussiotis VA, Kittas C, Pangalis GA. Vassilakopoulos TP, et al. Blood. 2005 Mar 1;105(5):1875-80. doi: 10.1182/blood-2004-01-0379. Epub 2004 Nov 9. Blood. 2005. PMID: 15536150 Free article.
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087. Chen R, et al. Among authors: vassilakopoulos tp. J Clin Oncol. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25. J Clin Oncol. 2017. PMID: 28441111 Free PMC article. Clinical Trial.
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH. Chen R, et al. Among authors: vassilakopoulos tp. Blood. 2019 Oct 3;134(14):1144-1153. doi: 10.1182/blood.2019000324. Epub 2019 Aug 13. Blood. 2019. PMID: 31409671 Free PMC article. Clinical Trial.
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis.
Zinzani PL, Chen R, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Nahar A, Balakumaran A, Moskowitz CH. Zinzani PL, et al. Among authors: vassilakopoulos tp. Leuk Lymphoma. 2020 Apr;61(4):950-954. doi: 10.1080/10428194.2019.1702178. Epub 2020 Jan 6. Leuk Lymphoma. 2020. PMID: 31905294 Free PMC article. No abstract available.
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.
Noerenberg D, Briest F, Hennch C, Yoshida K, Hablesreiter R, Takeuchi Y, Ueno H, Staiger AM, Ziepert M, Asmar F, Locher BN, Toth E, Weber T, Amini RM, Klapper W, Bouzani M, Poeschel V, Rosenwald A, Held G, Campo E, Ishaque N, Stamatopoulos K, Kanellis G, Anagnostopoulos I, Bullinger L, Goldschmidt N, Zinzani PL, Bödör C, Rosenquist R, Vassilakopoulos TP, Ott G, Ogawa S, Damm F. Noerenberg D, et al. Among authors: vassilakopoulos tp. J Clin Oncol. 2024 Feb 1;42(4):452-466. doi: 10.1200/JCO.23.01053. Epub 2023 Dec 6. J Clin Oncol. 2024. PMID: 38055913
BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens.
Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Viviani S, Bonfante V, Nadali G, Herling M, Angelopoulou MK, Giardini R, Chilosi M, Kittas C, McDonnell TJ, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. Rassidakis GZ, et al. Among authors: vassilakopoulos tp. Blood. 2002 Dec 1;100(12):3935-41. doi: 10.1182/blood.V100.12.3935. Blood. 2002. PMID: 12433696 Free article.
Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
Kalpadakis C, Pangalis GA, Dimopoulou MN, Vassilakopoulos TP, Kyrtsonis MC, Korkolopoulou P, Kontopidou FN, Siakantaris MP, Dimitriadou EM, Kokoris SI, Tsaftaridis P, Plata E, Angelopoulou MK. Kalpadakis C, et al. Among authors: vassilakopoulos tp. Hematol Oncol. 2007 Sep;25(3):127-31. doi: 10.1002/hon.820. Hematol Oncol. 2007. PMID: 17514771
Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphoma.
Dimou M, Angelopoulou MK, Pangalis GA, Georgiou G, Kalpadakis C, Pappi V, Tsopra O, Koutsoukos K, Zografos E, Boutsikas G, Moschogianni M, Vardounioti I, Petevi K, Karali V, Kanellopoulos A, Ntalageorgos T, Yiakoumis X, Bartzis V, Bitsani A, Pessach E, Efthimiou A, Korkolopoulou P, Rassidakis G, Kyrtsonis MC, Patsouris E, Meletis J, Panayiotidis P, Vassilakopoulos TP. Dimou M, et al. Among authors: vassilakopoulos tp. Leuk Lymphoma. 2012 Aug;53(8):1481-7. doi: 10.3109/10428194.2012.660628. Epub 2012 Apr 2. Leuk Lymphoma. 2012. PMID: 22280533
206 results